Cargando…

A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets

Epidermal Nevus Syndrome (ENS), also known as Cutaneous Skeletal Hypophosphatemia Syndrome or Linear Sebaceous Nevus Syndrome, is caused by a mosaic somatic mutation of RAS (Rat Sarcoma genes) which leads to abnormally elevated levels of fibroblast growth factor 23 (FGF23). FGF23 is a major regulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Carson, Gillis, Andrea, Fazendin, Jessica, Abdullatif, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309659/
https://www.ncbi.nlm.nih.gov/pubmed/35899095
http://dx.doi.org/10.1016/j.bonr.2022.101605
_version_ 1784753216153452544
author Huynh, Carson
Gillis, Andrea
Fazendin, Jessica
Abdullatif, Hussein
author_facet Huynh, Carson
Gillis, Andrea
Fazendin, Jessica
Abdullatif, Hussein
author_sort Huynh, Carson
collection PubMed
description Epidermal Nevus Syndrome (ENS), also known as Cutaneous Skeletal Hypophosphatemia Syndrome or Linear Sebaceous Nevus Syndrome, is caused by a mosaic somatic mutation of RAS (Rat Sarcoma genes) which leads to abnormally elevated levels of fibroblast growth factor 23 (FGF23). FGF23 is a major regulator in phosphate homeostasis. There are multiple disorders, along with Epidermal Nevus Syndrome (ENS), that result in unusually high circulating levels of FGF23. This increase ultimately leads to renal phosphate wasting and reduced levels of 1,25-dihydroxy vitamin D. Across these disorders, the clinical symptoms are similar and often include osteomalacia (hypophosphatemic rickets in children), muscle weakness, fatigue, joint deformities, bone pain, and fractures. Burosumab (KRN23), is an IgG1 monoclonal antibody that binds to the FGF23 receptor and inhibits the activity of FGF23. This leads to an increase in serum phosphate levels. Burosumab emerged as a potential therapy in FGF23 overactivity disorders. Burosumab was successful in the treatment of X-linked hypophosphatemia (XLH) and is now FDA-approved for its treatment. Studies have indicated that Burosumab therapy in subjects with XLH consistently increases and sustains serum phosphorus levels and tubular reabsorption of phosphate without a major impact on urine calcium levels or vitamin D metabolism. We studied the effect of Burosumab treatment in a single pediatric patient with Epidermal Nevus Syndrome. Serum phosphorus rose gradually as we titrated the dose of Burosumab upwards. During treatment, a persistent elevation of parathyroid hormone levels was noted along with a persistent elevation of serum calcium. We presumed the patient had tertiary hyperparathyroidism. However, after the removal of three parathyroid glands, the pathology came back with a single enlarged parathyroid adenoma. Subsequently, his calcium and PTH, and phosphorus levels stabilized while taking only Burosumab. ClinicalTrials.gov NCT04320316.
format Online
Article
Text
id pubmed-9309659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93096592022-07-26 A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets Huynh, Carson Gillis, Andrea Fazendin, Jessica Abdullatif, Hussein Bone Rep Full Length Article Epidermal Nevus Syndrome (ENS), also known as Cutaneous Skeletal Hypophosphatemia Syndrome or Linear Sebaceous Nevus Syndrome, is caused by a mosaic somatic mutation of RAS (Rat Sarcoma genes) which leads to abnormally elevated levels of fibroblast growth factor 23 (FGF23). FGF23 is a major regulator in phosphate homeostasis. There are multiple disorders, along with Epidermal Nevus Syndrome (ENS), that result in unusually high circulating levels of FGF23. This increase ultimately leads to renal phosphate wasting and reduced levels of 1,25-dihydroxy vitamin D. Across these disorders, the clinical symptoms are similar and often include osteomalacia (hypophosphatemic rickets in children), muscle weakness, fatigue, joint deformities, bone pain, and fractures. Burosumab (KRN23), is an IgG1 monoclonal antibody that binds to the FGF23 receptor and inhibits the activity of FGF23. This leads to an increase in serum phosphate levels. Burosumab emerged as a potential therapy in FGF23 overactivity disorders. Burosumab was successful in the treatment of X-linked hypophosphatemia (XLH) and is now FDA-approved for its treatment. Studies have indicated that Burosumab therapy in subjects with XLH consistently increases and sustains serum phosphorus levels and tubular reabsorption of phosphate without a major impact on urine calcium levels or vitamin D metabolism. We studied the effect of Burosumab treatment in a single pediatric patient with Epidermal Nevus Syndrome. Serum phosphorus rose gradually as we titrated the dose of Burosumab upwards. During treatment, a persistent elevation of parathyroid hormone levels was noted along with a persistent elevation of serum calcium. We presumed the patient had tertiary hyperparathyroidism. However, after the removal of three parathyroid glands, the pathology came back with a single enlarged parathyroid adenoma. Subsequently, his calcium and PTH, and phosphorus levels stabilized while taking only Burosumab. ClinicalTrials.gov NCT04320316. Elsevier 2022-07-20 /pmc/articles/PMC9309659/ /pubmed/35899095 http://dx.doi.org/10.1016/j.bonr.2022.101605 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Full Length Article
Huynh, Carson
Gillis, Andrea
Fazendin, Jessica
Abdullatif, Hussein
A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
title A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
title_full A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
title_fullStr A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
title_full_unstemmed A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
title_short A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets
title_sort case report to assess the safety and efficacy of burosumab, an investigational antibody to fgf23, in a single pediatric patient with epidermal nevus syndrome and associated hypophosphatemic rickets
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309659/
https://www.ncbi.nlm.nih.gov/pubmed/35899095
http://dx.doi.org/10.1016/j.bonr.2022.101605
work_keys_str_mv AT huynhcarson acasereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT gillisandrea acasereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT fazendinjessica acasereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT abdullatifhussein acasereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT huynhcarson casereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT gillisandrea casereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT fazendinjessica casereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets
AT abdullatifhussein casereporttoassessthesafetyandefficacyofburosumabaninvestigationalantibodytofgf23inasinglepediatricpatientwithepidermalnevussyndromeandassociatedhypophosphatemicrickets